AnaptysBio, Inc. (ANAB), a clinical-stage biotechnology company, on Friday said its Board has approved an amended stock repurchase plan allowing the company to buy back up to $100 million of its stock.
The repurchase plan runs through March 31, 2026.
The new authorization comes as an addition to the $6.4 million remaining under its existing $75 million program, under which the company has repurchased 3,443,188 shares, representing 11.2% of shares outstanding at the plan's start.
The company expects to end 2025 with about $300 million in cash, cash equivalents and investments.
A one-time $75 million commercial sales milestone is anticipated from GSK in the fourth quarter of 2025 once Jemperli reaches $1 billion in global net sales.
On Thursday, AnaptysBio closed trading 1.76% higher at $37.66 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.